Strs Ohio Sells 2,155 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Strs Ohio cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,985 shares of the biopharmaceutical company’s stock after selling 2,155 shares during the period. Strs Ohio’s holdings in Alnylam Pharmaceuticals were worth $12,761,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Thematics Asset Management bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $1,995,000. Teacher Retirement System of Texas lifted its holdings in Alnylam Pharmaceuticals by 3.2% during the 2nd quarter. Teacher Retirement System of Texas now owns 36,408 shares of the biopharmaceutical company’s stock valued at $11,872,000 after purchasing an additional 1,123 shares during the last quarter. Generali Asset Management SPA SGR boosted its position in Alnylam Pharmaceuticals by 6,368.0% during the third quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock worth $1,475,000 after purchasing an additional 3,184 shares during the period. Rakuten Investment Management Inc. bought a new position in Alnylam Pharmaceuticals during the third quarter worth $14,205,000. Finally, Investment Management Corp of Ontario increased its holdings in shares of Alnylam Pharmaceuticals by 35.4% in the second quarter. Investment Management Corp of Ontario now owns 31,521 shares of the biopharmaceutical company’s stock valued at $10,279,000 after purchasing an additional 8,244 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Down 3.2%

Shares of ALNY opened at $357.98 on Monday. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55. The firm’s 50 day moving average is $409.91 and its 200-day moving average is $423.98. The stock has a market capitalization of $47.29 billion, a PE ratio of 1,491.58 and a beta of 0.32.

Wall Street Analyst Weigh In

ALNY has been the subject of a number of research reports. Barclays raised their target price on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Stifel Nicolaus increased their price target on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Jefferies Financial Group reduced their price objective on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a report on Thursday, October 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $489.00 target price (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Finally, Leerink Partners lowered their target price on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research note on Monday, December 15th. Twenty-two analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $485.21.

Insider Activity

In related news, EVP Pushkal Garg sold 1,510 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $547,933.70. Following the completion of the sale, the executive vice president owned 22,511 shares of the company’s stock, valued at $8,168,566.57. This represents a 6.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 9,577 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the sale, the chief executive officer owned 78,411 shares in the company, valued at $28,452,215.46. The trade was a 10.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 56,955 shares of company stock worth $24,072,733. 1.20% of the stock is owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.